Click on one of these terms to refine your search
10 literature results
-
Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).
OBJECTIVE: Cardiovascular disease (CVD) risk is increased in type 2 diabetes. The purpose of this study was to assess the effect of 10 mg of atorvasta…
Authors: Robert H Knopp, Michael d'Emden, Johan G Smilde, Stuart J Pocock
Source: Diabetes care. 2006 Jul
View Full Text -
Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
OBJECTIVE: We explored whether cardiovascular disease (CVD) risk and the effects of fenofibrate differed in subjects with and without metabolic syndro…
Authors: Russell Scott, Richard O'Brien, Greg Fulcher, Chris Pardy, Michael D'Emden, Dana Tse, Marja-Riitta Taskinen, Christian Ehnholm, Anthony Keech, Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators
Source: Diabetes care. 2009 Mar
View Free Full Text -
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
BACKGROUND: Patients with type 2 diabetes mellitus are at increased risk of cardiovascular disease, partly owing to dyslipidaemia, which can be amenab…
Authors: A Keech, R J Simes, P Barter, J Best, R Scott, M R Taskinen, P Forder, A Pillai, T Davis, P Glasziou,…
Source: Lancet. 2005 Nov 26
View Full Text -
Myocardial infarction and type II diabetes--preferential treatment for high risk patients?
OBJECTIVES: To compare variability of blood glucose concentration in patients with type II diabetes with (cases) and without (controls) myocardial inf…
Authors: B Green, S Duffull, N Cottrell, M D'Emden
Source: Journal of clinical pharmacy and therapeutics. 2002 Oct
View Full Text -
Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial.
OBJECTIVES: To assess the efficacy and tolerability of risedronate, a pyridinyl bisphosphonate, in preventing loss of bone mineral density (BMD) of th…
Authors: M J Hooper, P R Ebeling, A P Roberts, J J Graham, G C Nicholson, M D'Emden, T F Ernst, D Wenderoth
Source: Climacteric : the journal of the International Menopause Society. 2005 Sep
View Full Text -
Microvascular complications in cystic fibrosis-related diabetes mellitus: a case report.
CONTEXT, The prevalence of cystic fibrosis-related diabetes mellitus is increasing and is associated with increased survival from cystic fibrosis. CAS…
Authors: A I Scott, B E Clarke, H Healy, M D Emden, S C Bell
Source: JOP : Journal of the pancreas. 2000 Nov
View Full Text -
A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia.
We directly compared the safety and efficacy of atorvastatin and simvastatin in hypercholesterolemic patients. This 1-year, randomized, double-blind s…
Authors: A Dart, G Jerums, G Nicholson, M d'Emden, I Hamilton-Craig, G Tallis, J Best, M West, D Sullivan, P Bracs,…
Source: The American journal of cardiology. 1997 Jul 1
View Full Text -
Clustered point mutation analysis of the rat prolactin promoter.
To identify DNA regions important for basal and hormone-stimulated transcription of the rat PRL gene, a series of clustered point mutations were prepa…
Authors: R A Iverson, K H Day, M d'Emden, R N Day, R A Maurer
Source: Molecular endocrinology (Baltimore, Md.). 1990 Oct
View Full Text -
Is cholesterol testing/treatment really beneficial?
Authors: M d'Emden
Source: The Medical journal of Australia. 1994 Feb 21
View Full Text -
Pneumocystis thyroiditis.
Authors: A Patel, D Sowden, R Kemp, M D'Emden, D Perry-Keene
Source: The Medical journal of Australia. 1992 Jan 20
View Full Text
